Steven Cohen Janux Therapeutics, Inc. Transaction History
Point72 Asset Management, L.P.
- $40.1 Billion
- Q1 2025
A detailed history of Steven Cohen (Point72 Asset Management, L.P.) transactions in Janux Therapeutics, Inc. stock. As of the latest transaction made, Point72 Asset Management, L.P. holds 376,662 shares of JANX stock, worth $8.76 Million. This represents 0.03% of its overall portfolio holdings.
Number of Shares
376,662
Previous 621,383
39.38%
Holding current value
$8.76 Million
Previous $33.3 Million
69.43%
% of portfolio
0.03%
Previous 0.08%
Shares
4 transactions
Others Institutions Holding JANX
# of Institutions
195Shares Held
57.3MCall Options Held
626KPut Options Held
155K-
Ra Capital Management, L.P. Boston, MA11.2MShares$260 Million6.27% of portfolio
-
Janus Henderson Group PLC London, X04.6MShares$107 Million0.07% of portfolio
-
Adage Capital Partners Gp, L.L.C. Boston, MA3.65MShares$85 Million0.19% of portfolio
-
Paradigm Biocapital Advisors LP New York, NY3.33MShares$77.5 Million4.61% of portfolio
-
Black Rock Inc. New York, NY2.34MShares$54.5 Million0.0% of portfolio
About Janux Therapeutics, Inc.
- Ticker JANX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 41,663,000
- Market Cap $969M
- Description
- Janux Therapeutics, Inc., a biopharmaceutical company, develops therapeutics based on proprietary Tumor Activated T Cell Engager (TRACTr) platform technology to treat patients suffering from cancer. The company's lead TRACTr product candidates that are in preclinical or discovery stage target prostate-specific membrane antigen, epidermal growth ...